Hehai Pan

Dr. Hehai Pan

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AFAshley M. Fuller
Ashley M. Fuller
HPHawley C. Pruitt
Hawley C. Pruitt
YLYing Liu
Ying Liu
VIValerie M. Irizarry-Negron
Valerie M. Irizarry-Negron
HPHehai Pan
Hehai Pan
TETzipora S.Karin Eisinger-Mathason
Tzipora S.Karin Eisinger-Mathason
CD8 + T cell dysfunction impedes antitumor immunity in solid cancers, but the underlying mechanisms are diverse and poorly understood. Extracellular matrix (ECM) composition has been linked to impaired T cell migration and enhanced tumor progression; however, impacts of individual ECM molecules on T cell function in the tumor microenvironment (TME) are only beginning to be elucidated. Upstream regulators of aberrant ECM deposition and organization in solid tumors are equally ill-defined. Therefore, we investigated how ECM composition modulates CD8 + T cell function in undifferentiated pleomorphic sarcoma (UPS), an immunologically active desmoplastic tumor. Using an autochthonous murine model of UPS and data from multiple human patient cohorts, we discovered a multifaceted mechanism wherein the transcriptional coactivator YAP1 promotes collagen VI (COLVI) deposition in the UPS TME. In turn, COLVI induces CD8 + T cell dysfunction and immune evasion by remodeling fibrillar collagen and inhibiting T cell autophagic flux. Unexpectedly, collagen I (COLI) opposed COLVI in this setting, promoting CD8 + T cell function and acting as a tumor suppressor. Thus, CD8 + T cell responses in sarcoma depend on oncogene-mediated ECM composition and remodeling.